Fit-For-Purpose Lipids Can Accelerate, Scale, And Improve RNA-LNP Drugs

Emerging biotech companies are investing in novel delivery capabilities to address the needs of different modalities and extra-hepatic delivery. For RNA-LNP drugs, the drug delivery foundation is only as strong as the lipid formulation. The lipid component of an LNP is essential for clinical translation and can be optimized for structural properties and additional functionalities. Lipids promote key LNP features and influence nucleic acid protection, formulation stability, and drug release. Therefore, lipids play a crucial role in lipid-based RNA therapeutics scaling through clinical development to commercialization.

As drug development is lengthy and costly, developing new formulations at the discovery stage is required. Rapid validation of lipids drives growth in the genomic medicine toolbox to encapsulate varied payloads, target different cell types and tissues, and manufacture products at various scales. Access to quality lipids and optimization expertise can provide a competitive advantage and accelerate development and manufacturing by reducing the number of lipid formulation steps, simplifying the process, and reducing costs. Explore steps to accelerate the delivery of commercial nanomedicines.